Key facts
- This page summarizes William P. Forbes's Form 4 filing for Trevi Therapeutics, Inc. (TRVI).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Jul 2022, 16:49.
William P. Forbes - 29 Jun 2022 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- TRVI
- Reported as of
- 29 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2022, 16:49:50 UTC
- Prior SEC filing
- 07 Mar 2022
- Next SEC filing
- 20 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Galletta, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William P. Forbes filed Form 4 for Trevi Therapeutics, Inc. (TRVI) on 01 Jul 2022.
Change
- Previous filing in this sequence was filed on 07 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRVI
transaction
Derivative
Performance Stock Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +48,000
- Change %
- Price
- $0.000000
- Shares after
- 48,000
- Date
- 29 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,000
- Exercise price
- $3.21
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 60,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On June 29, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that certain performance metrics related to the successful results of the PRISM trial were satisfied, resulting in the vesting of the option as to 48,000 shares of common stock. The performance-based option remains eligible for vesting with respect to the remaining shares of common stock underlying the option in the event that additional performance metrics related to the successful results of the CANAL trial are satisfied.